Nymox Pharmaceutical Corp. (NASDAQ: NYMX) has been around for a long time, but within the past five years the stock has literally fallen off a cliff. Suddenly, its shares rallied over 100% in the past week. The question for investors remains whether this jump was a fluke or if Nymox is really back in business.
Nymox announced Wednesday that is undertaking further analysis of its pivotal Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will include new long-term data from Studies NX02-0017 and NX02-0018. Ultimately, the company expects to provide these new pivotal Phase 3 study results in the second or early third quarter of this year.
The NX02-0017 and NX02-0018 studies were initiated in 2009. NX02-0017, which consisted of 499 patients randomized, was completed in 2012. NX02-0018 had 498 randomized patients and was completed in 2013. At 12 months post-treatment, there was no overall top-line statistical significance for the efficacy of treatment in terms of BPH Symptom Score improvement versus controls. The safety profile of NX-1207 was excellent.
ALSO READ: Does the Mylan Secondary Make Its Stock Cheap?
Dr. Paul Averback, CEO of Nymox, commented on this undertaking:
Despite the setback of top-line results not initially beating controls statistically at 12 months post-treatment in these large studies, we continue to believe that NX-1207 has enormous potential for long-term management of BPH. Additional new blinded protocol data from the same pivotal studies is being prospectively captured in order to assess long-term results in patients up to 5 years after a single injection of NX-1207 2.5 mg vs placebo.
The company also reported its financial results just the day before this announcement was made. Nymox reported a net loss of $0.13 per share on a mere $331,909 in revenue for the year ended in December 2014.
At the same time, NX-1207 is also in late-stage development for low grade localized prostate cancer. Note that in 2014, Nymox reported eight-month efficacy results showing statistically significant reduced cancer progression in patients who received NX-1207 compared to standard of care.
Nymox shares began their run on Tuesday, moving up 27% to close at $0.84. The stock continued its climb on Wednesday, up 50% to $1.26. Finally, shares of Nymox closed Thursday up 37.6% to $1.73, in a 52-week trading range of $0.33 to $5.76. The stock has a consensus analyst price target of $10.25.
ALSO READ: Dyax Sees Big Increases in Analyst Price Targets
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.